BioCity Biopharma CD3/EGFR Bispecific Antibody Granted FDA Clearance for IND Application

BioCity Biopharma has received clearance from the U.S. Food and Drug Administration (FDA) to proceed with an Investigational New Drug (IND) application for their experimental drug BC3448 to conduct a Phase 1 study of BC3448, a CD3/EGFR bispecific antibody (BsAb).

BC3448 is a CD3-based bispecific antibody (BsAb) designed to attract T cells to tumour cells displaying elevated EGFR expression, leading to T cell-mediated destruction of the tumour cells. To mitigate the risk of cytokine release syndrome (CRS), a potential complication linked to CD3-based BsAbs, BC3448 is engineered with distinct binding affinities for EGFR and CD3.

BC3448 is under development for solid tumours characterised by significant EGFR expression, such as NSCLC, HNSCC, mCRC, and ESC. In preclinical investigations, BC3448 exhibited notable antitumor effects across various tumour categories exhibiting elevated EGFR levels. BC3448 holds promise as a potential therapy for EGFR-expressing tumours, for those unresponsive to treatments like EGFR-TKI and EGFR monoclonal antibodies (mAbs).

Currently, a limited number of CD3/EGFR bispecific antibodies (BsAbs) are undergoing clinical development on a global scale. Among these programmes, BC3448 stands out as one of the forefront candidates. 

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!